期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

强直性脊柱炎的目标治疗时代到来了吗 被引量：4

原文传递
导出
摘要 近十年来，无论是在基础研究还是在临床诊治方面，AS/SpA都取得了许多重要的进展。在临床方面最重要的进展包括TNF抑制剂的应用，它在很大程度上改变了AS／SpA的治疗方法，使其治疗进入生物制剂时代。
作者 邓小虎 黄烽
机构地区 解放军总医院风湿科
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2016年第7期433-436,共4页 Chinese Journal of Rheumatology
关键词 目标治疗 强直性脊柱炎 TNF抑制剂 临床诊治 治疗方法 生物制剂 SPA
分类号 R593.23 [医药卫生—内科学]
  • 相关文献

参考文献23

  • 1Rudwaleit M, van der Heijde D, Landewe R, et al. The de- velopment of Assessment of Spondylo arthritis International So- ciety classification criteria for axial spondyloarthritis (part II ): validation and final selection[J]. Ann Rheum Dis, 2009, 68: 777-783. DOI: 10.1136/ard.2009.108233.
  • 2Rudwaleit M, van der Heijde D, Landewe R, et al. The Assess- ment of Spondylo arthritis International Society classification cri- teria for peripheral spondyloarthritis and for spondyloarthritis in general[J]. Ann Rheum Dis, 2011, 70: 25-31. DOI: 10.1136/ard. 2010.133645.
  • 3Sieper J, van der Heijde. Nonradiographic axial spondyloarthri- tis: new definition of an old disease? [J]. Arthritis Rheumatol, 2013, 65: 543-551. DOI: 10.1002/art.37803.
  • 4邓小虎,黄烽.强直性脊柱炎的目标治疗[J].中华医学杂志,2011,91(11):725-729. 被引量：15
  • 5Ward MM, Deodhar A, Elie A, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthri- tis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis[J]. Arthritis Rheumatol, 2016, 68: 282-298. DOI: 10.1002/art.39298.
  • 6Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis[J]. Ann Rheum Dis, 2011, 70: 896-904. DOI: 10.1136/ard.2011.151027.
  • 7Smolen JS, Braun J, Dougados M, et al. Treating spondy- loarthritis, including ankylosing spondylitis and psoriatic arthri- tis, to target: recommendations of an international task force[J]. Ann Rheum Dis, 2014, 73: 6-16. DOI: 10.1136/annrheumdis- 2013-203419.
  • 8Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables[J]. J Clin Epidemiol, 2011, 64: 383-394. DOI: 10.1016/j. jclinepi.2010.04.026.
  • 9李坤鹏,黄烽.强直性脊柱炎：一种被忽视的全身性疾病[J].中华内科杂志,2015,54(11):913-915. 被引量：11
  • 10徐胜前,黄烽.应重视放射学阴性中轴型脊柱关节炎的存在[J].中华风湿病学杂志,2016,20(2):73-76. 被引量：1

二级参考文献54

  • 1黄烽,张莉芸,张江林,张奉春,梁东风,邓小虎,郭军华,朱剑,赵伟,李小峰,侯勇.抗肿瘤坏死因子α单克隆抗体治疗强直性脊柱炎的短期临床观察[J].中华内科杂志,2006,45(2):122-126. 被引量：21
  • 2朱剑,黄烽,张莉芸,张江林,张奉春,候勇,余德恩.寻找预测强直性脊柱炎患者接受3次infliximab治疗后10周病情改善及复发的指标[J].中华风湿病学杂志,2007,11(5):288-292. 被引量：9
  • 3Zhang S, Li Y, Deng X, et al. Similarities and differences between spondyloarthritis in Asia and other parts of the world. Curr Opin Rheumato1,2011,23 :334-338.
  • 4Baraliakos X, Listing J, Brandt J, et al. Clinical response todiscontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther,2005,7 :R439-444.
  • 5Marzo-Ortega H, McGonagle D, Jarrett S, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis, 2005,64: 1568-1575.
  • 6Lee SH, Lee YA, Hong SJ, et al. Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin Rheumato1,2008,27 : 179 -181.
  • 7Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology ( Oxford ), 2005,44 : 342-348.
  • 8Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther,2011,13 :R105.
  • 9Arends S, Brouwer E, van der Veer E, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis : a prospective longitudinal observational cohort study. Arthritis Res Ther,2011, 13 :R94.
  • 10Collantes-Estevez E, Mufioz-Villanueva MC, Zarco P, et al. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a muhieentre study. Rheumatology ( Oxford ) , 2005,44 : 1555-1558.

共引文献30

同被引文献30

引证文献4

二级引证文献45

中华风湿病学杂志
2016年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部